<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647488</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280D2201</org_study_id>
    <secondary_id>2018-001420-19</secondary_id>
    <nct_id>NCT03647488</nct_id>
  </id_info>
  <brief_title>Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase II Multicenter Randomized Two-arm Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Pretreated Adult Patients With EGFR Wild-type ALK Rearrangement Negative Advanced/Metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical research study and the purpose of the study is to learn whether the
      combination of the drugs capmatinib plus spartalizumab helps to control lung cancer better
      compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to
      patients with NSCLC.

      Capmatinib is an oral drug that is called a &quot;targeted&quot; medicine: this means it targets
      particular processes, which may not be working properly in the cancer cells in your body
      (called dysregulation) and which may be causing your disease.

      Spartalizumab is an antibody (a kind of protein that binds to a specific &quot;target&quot; protein).
      By blocking its &quot;target&quot; protein, called PD-1, spartalizumab may increase the activity of a
      certain type of cells in your immune system, which may reduce the growth of your tumor.

      Docetaxel is a standard chemotherapy medicine commonly used to treat your type of lung
      cancer. This standard, anti-cancer medicine is a cytotoxic chemotherapy that is being
      compared with capmatinib and spartalizumab.

      The reason for this study is to find out which of these two treatments (combination of
      capmatinib plus spartalizumab OR docetaxel alone) helps to control lung cancer better.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 26, 2018</start_date>
  <completion_date type="Anticipated">November 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Run in part: Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>after all participants have completed 24 weeks of follow-up, approximately 11 months</time_frame>
    <description>to assess safety and tolerability of capmatinib and spartalizumab combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomized part: Overall survival (OS)</measure>
    <time_frame>after 60 events have been observed, approximately 18 months</time_frame>
    <description>Overall Survival (OS) is defined as the time from date of randomization to date of death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>after 60 OS events are observed, approximately 18 months</time_frame>
    <description>Objective response rate is defined as the proportion of subjects with best overall response (BOR) of complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>after 60 OS events are observed, approximately 18 months</time_frame>
    <description>Disease control rate is defined as the proportion of subjects with best overall response of complete response or partial response or stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>after 60 OS events are observed, approximately 18 months</time_frame>
    <description>Progression free survival is defined as the time from the date of randomization (randomized part) or start of treatment (run-in part) to the date of the first documented radiological progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>after 60 OS events are observed, approximately 18 months</time_frame>
    <description>Time to response (TTR) is defined as the time from the date of randomization (randomized part) or start of treatment (run-in part) to the first documented response of either complete response or partial response, which must be subsequently confirmed (although date of initial response is used, not date of confirmation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>after 60 OS events are observed, approximately 18 months</time_frame>
    <description>Duration of response only applies to subjects for whom best overall response is complete response or partial response. DOR is defined as the time between the date of first documented response (CR or PR) and the date of first documented progression or death due to underlying cancer. If progression or death due to underlying cancer has not occurred, then the subject is censored at the date of last adequate tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12 months and then every 6 months until treatment discontinuation, and then 3 and 5 months after treatment discontinuation</time_frame>
    <description>The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12 months and then every 6 months until treatment discontinuation, and then 3 and 5 months after treatment discontinuation</time_frame>
    <description>The AUC calculated to the end of a dosing interval (tau) at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12 months and then every 6 months until treatment discontinuation, and then 3 and 5 months after treatment discontinuation</time_frame>
    <description>The maximum (peak) observed plasma serum concentration after single dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12 months and then every 6 months until treatment discontinuation, and then 3 and 5 months after treatment discontinuation</time_frame>
    <description>Ctrough is defined as the minimum (peak) observed plasma serum concentration (mass x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12 months and then every 6 months until treatment discontinuation, and then 3 and 5 months after treatment discontinuation</time_frame>
    <description>Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T 1/2</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12 months and then every 6 months until treatment discontinuation, and then 3 and 5 months after treatment discontinuation</time_frame>
    <description>The elimination half-life associated with the terminal slope (lz) of a semi logarithmic concentration-time curve (time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity, characterized by tabulating anti-drug antibodies (ADA) prevalence at baseline and ADA incidence on-treatment</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 10, 12 months and then every 6 months until treatment discontinuation, and then 3 and 5 months after treatment discontinuation</time_frame>
    <description>Antidrug antibodies (ADA) prevalence at baseline and ADA incidence on treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Capmatinib plus spartalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capmatinib</intervention_name>
    <description>Tablets, given orally</description>
    <arm_group_label>Capmatinib plus spartalizumab</arm_group_label>
    <other_name>INC280</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spartalizumab</intervention_name>
    <description>Concentrate for solution for infusion, intravenous use</description>
    <arm_group_label>Capmatinib plus spartalizumab</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Concentrate for solution for infusion, intravenous use</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed locally advanced/metastatic (stage IIIB/IV), EGFR wild-type,
             ALK rearrangement negative, non-small cell lung cancer

          -  Subject has demonstrated progression following one prior platinum doublet and one
             prior PD-(L)1 checkpoint inhibitor (either alone or in combination, the most recent
             treatment regimen must have contained a PD-(L)1 checkpoint inhibitor)

          -  Subjects must be candidates for single agent docetaxel

          -  Subjects must have at least one lesion evaluable by RECIST 1.1

        Exclusion Criteria:

          -  Prior treatment with a MET inhibitor or HGF (Hepatocyte growth factor) targeting
             therapy

          -  Any untreated central nervous system (CNS) lesion

          -  Use of any live vaccines against infectious diseases within 12 weeks of initiation of
             study treatment.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>LILLE CÃ©dex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
    <country>Japan</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>July 26, 2020</last_update_submitted>
  <last_update_submitted_qc>July 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small-cell lung carcinoma</keyword>
  <keyword>Non-small-cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>epidermal growth factor receptor wild type</keyword>
  <keyword>EGFRwt</keyword>
  <keyword>Anaplastic lymphoma kinase negative</keyword>
  <keyword>ALK-</keyword>
  <keyword>INC280</keyword>
  <keyword>capmatinib and spartalizumab</keyword>
  <keyword>combination therapy</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

